Product information

From Health Canada

No match found

No other product was found with the same active ingredient group.

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Approved

Current status date:

2020-02-19

Product name:

XOFLUZA

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02496372

Product Monograph/Veterinary Labelling:

Date: 2022-01-12 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

HOFFMANN-LA ROCHE LIMITED
7070 Mississauga Road
Mississauga
Ontario
Canada L5N 5M8

Class:

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

08:18.92 

Anatomical Therapeutic Chemical (ATC): See footnote 4

J05AX25 BALOXAVIR MARBOXIL

Active ingredient group (AIG) number:See footnote5

0162036002

List of active ingredient(s)
Active ingredient(s) See footnote8 Strength
BALOXAVIR MARBOXIL 40 MG
Version 4.0.3

"Page details"

Date modified: